TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11773176
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (PCT) consisting of two cycles of mitomycin (6 mg/m(2), day 1), ifosfamide (1.5 g/m(2), days 1 to 3), and cisplatin (30 mg/m(2), days 1 to 3), plus two additional postoperative cycles for responding patients.
Study: 30408319
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (PCT)
Study: 2511687
Drug: Intravenous isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isosorbide dinitrate (mean dose 12.9 mg; range 7.7‐14.9)
Study: 2511687
Drug: Buccal nitroglycerine
Normalized name: nitroglycerin Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal nitroglycerine (5 mg)
Study: 2511687
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (nitro TTS 10)
Study: 1066200
Drug: Zirconium silicate
Normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zirconium silicate paste containing 9% stannous fluoride (Zircate Treatment Paste) applied every 6 months
Study: 1066200
Drug: Zirconium silicate
Normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zirconium silicate paste containing 9% stannous fluoride (Zircate Treatment Paste) applied once each year
Study: 31248461
Drug: 12MP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12MP + Tet + TLR agonist without IFA (V0)
Study: 31248461
Drug: 12MP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12MP + Tet + TLR agonist with IFA (V1)
Study: 31248461
Drug: 12MP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12MP + Tet + TLR agonist with IFA (V6)
Study: 31248461
Drug: Treatment-related dose-limiting
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related dose-limiting toxicities (DLTs)
Study: 12117049
Drug: TJ-96 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ-96 (2.5 g orally 3 times daily for 4 weeks)
Study: 23522721
Drug: NSAID therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID therapy (n=24)
Study: 23522721
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (n=11)
Study: 18413332
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg extended-release fluvastatin every day
Study: 18413332
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg immediate-release fluvastatin twice a day
Study: 10832825
Drug: Diltiazem 300
Normalized name: diltiazem 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 300 mg oral once daily for up to 6 months
Study: 9093182
Drug: Early follicular
Normalized name: Follicular hormone
DrugBank: Estrone (DB00655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early follicular endometrial priming with 2 mg 17 beta‐E2 twice per day (group A)
Study: 9093182
Drug: Midfollicular endometrial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midfollicular endometrial priming with 1 to 2 mg/d of 17 beta‐E2 (group B)
Study: 8457235
Drug: Piracetam 4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 4.8 g
Study: 8457235
Drug: Piracetam 9.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 9.6 g
Study: 8457235
Drug: Piracetam (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (4.8 g and 9.6 g)
Study: 3954834
Drug: 0.58 g
Normalized name: LACTIC ACID 0.58 g in 100 g TOPICAL LIQUID [Atlas Prep Activator]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.58 g alcohol/kg body wt as whisky or lager
Study: 31175689
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein dose (exact dosage not specified)
Study: 31175689
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein dose (exact dosage not specified)
Study: 27246689
Drug: Bevacizumab (BEV)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BEV) plus cytotoxic chemotherapy
Study: 27246689
Drug: Bevacizumab (BEV)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BEV) 15 mg/kg dosing
Study: 27246689
Drug: Bevacizumab (BEV)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BEV) 10 mg/kg dosing
Study: 25705005
Drug: Paclitaxel drug-eluting
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel drug-eluting balloon (DEB)
Study: 10379631
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of tubocurarine (TC) 0.15 mg x kg(‐1)
Study: 10379631
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of vecuronium (VEC) 0.015 mg x kg(‐1)
Study: 10379631
Drug: Intubation dose
Normalized name: ADAPTER,INTUBATION CAREFUSION #1820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intubation dose of tubocurarine (TC) 0.6 mg x kg(‐1)
Study: 8704079
Drug: Metamizol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol (1 g/100 ml NaCl 0.9% intravenous over 15 min) plus diclofenac (100 mg suppository)
Study: 1473857
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g paracetamol coingested with a meal of white bread
Study: 1473857
Drug: White bread
Normalized name: White bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: White bread meal without paracetamol
Study: 31633318
Drug: Ultrasonic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic preparation (Crown Prep, Mectron, Carasco, Italy)
Study: 31633318
Drug: Ultrasonic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic preparation
Study: 23909911
Drug: Development of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Development of nephropathy (incidence of urinary albumin excretion rate > 40 mg/24 h)
Study: 23909911
Drug: Progression of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progression of retinopathy (3-step change in Early Treatment Diabetic Retinopathy Study score)
Study: 19049340
Drug: ACE-011 (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-011 (0.01 to 3.0 mg/kg intravenously or 0.03 to 0.1 mg/kg subcutaneously)
Study: 23144826
Drug: Disulfiram (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (250 mg/d)
Study: 11732275
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (600 IU daily) and selegiline (10 mg daily)
Study: 9206238
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment (Control)
Study: 9164205
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin 50 mg/m2 for nine courses
Study: 9164205
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 plus cyclophosphamide 750 mg/m2 every 21 days for six courses
Study: 9725478
Drug: Megaloporous sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megaloporous sustained-release tablets
Study: 9725478
Drug: Hydrophil matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrophil matrix tablets
Study: 9725478
Drug: Floating slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floating slow-release tablets with food
Study: 9725478
Drug: Floating slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floating slow-release tablets without food
Study: 9725478
Drug: Rapid release
Normalized name: Mapap Rapid Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid release oxprenolol tablets
Study: 9725478
Drug: Fasting tablets
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting tablets (sustained-release)
Study: 7913498
Drug: E2078 (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2078 (5.0 to 10.0 mg, i.m.)
Study: 7913498
Drug: E2078 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2078 (single dose)
Study: 7913498
Drug: E2078 (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2078 (repeated dose, 5.0 mg t.i.d. for 4 and 1/3 days)
Study: 7913498
Drug: E2078 (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2078 (repeated doses)
Study: 7913498
Drug: E2078 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2078 (single administration)
Study: 11891095
Drug: Carbamazepine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (15 mg/kg per day)
Study: 11891095
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (20-25 mg/kg per day)
Study: 30101910
Drug: Adjusted R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted R-CHOP doses according to a unified dose-attenuation system (UNI group)
Study: 30101910
Drug: Adjusted R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted R-CHOP doses according to physicians' decisions (PHY group)
Study: 22366446
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) - 12 twice-weekly 60 min sessions
Study: 18691211
Drug: Standard practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard practice of EMS transfer and ED treatment (Control).
Study: 15764767
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP), 250 microg ex-valve (220 microg ex-actuator) four puffs twice daily
Study: 15764767
Drug: Ciclesonide (CIC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide (CIC), 200 microg ex-valve (160 microg ex-actuator) four puffs twice daily
Study: 26795874
Drug: Rivastigmine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (12 mg per day after uptitration from 3 mg per day over 12 weeks)
Study: 20943882
Drug: 3-dose PCV
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-dose PCV
Study: 20943882
Drug: 2-dose PCV
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-dose PCV
Study: 20943882
Drug: 0-dose PCV
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0-dose PCV
Study: 11991475
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT) - 3 sessions of 3000 shockwaves/session at 0.2 mJ/mm2, weekly intervals for Group 1 (25 heels)
Study: 11991475
Drug: Conventional conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional conservative treatment (nonsteroidal anti‐inflammatory drugs, heel cup, orthoses and/or shoe modifications, local steroid injections, electrotherapy) for Group 2 (24 heels)
Study: 7800166
Drug: SER282 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SER282 (20 mg/ml)
Study: 7800166
Drug: Amitryptiline (AMI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitryptiline (AMI, 50 mg)
Study: 3154631
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil 240 mg
Study: 168650
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Clofibate or Colestipol, or Clofibrate and Cholestyramine)
Study: 30316810
Drug: Binge drinking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binge drinking (consumption of five or more doses of alcohol on a single occasion)
Study: 30316810
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of inhalant drugs
Study: 25736589
Drug: High-intensity resistance
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity resistance training (3 times weekly for 16 weeks)
Study: 22575238
Drug: Intravesical valrubicin
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical valrubicin (800 mg) instillations, 6 weekly doses
Study: 22575238
Drug: Intravesical valrubicin
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical valrubicin (800 mg) instillations, 9 weekly doses
Study: 22575238
Drug: Intravesical valrubicin
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical valrubicin (800 mg) instillations, 6 weekly doses (pivotal trial)
Study: 22575238
Drug: Intravesical valrubicin
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical valrubicin (800 mg) instillations
Study: 21715575
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg MF59 adjuvanted vaccine
Study: 21715575
Drug: 3.75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 μg MF59 adjuvanted vaccine
Study: 21715575
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg nonadjuvanted vaccine
Study: 21715575
Drug: MF59 adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59 adjuvanted vaccines
Study: 11691700
Drug: Enhanced consent
Normalized name: Consensi
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enhanced consent procedure (computerized presentation with sequential bullet points and summaries)
Study: 8104596
Drug: Remission induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remission induction with vincristine (VCR), prednisolone (PRED), and L-asparaginase (L-Asp)
Study: 8104596
Drug: Reinforcement cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcement cycles during maintenance therapy (6-mercaptopurine+MTX)
Study: 3097178
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (0.22 mg X kg‐1, range 0.15‐0.38)
Study: 3097178
Drug: Rectal diazepam
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diazepam (0.58 mg X kg‐1, range 0.50‐0.71)
Study: 3097178
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and rectal diazepam
Study: 27896908
Drug: Bixalomer (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bixalomer (1500 mg/day adjusted up to 7500 mg/day)
Study: 17213007
Drug: Esomeprazole 5
Normalized name: esomeprazole 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 5 mg
Study: 17213007
Drug: Esomeprazole 10
Normalized name: esomeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 10 mg
Study: 25250612
Drug: Esomeprazole 10
Normalized name: esomeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 10 mg (for patients >= 20 kg)
Study: 20434606
Drug: Nabilone (0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (0.5mg once a day, with option to increase to 0.5mg twice a day)
Study: 12514774
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1000 mg orally twice daily
Study: 12514774
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 500 mg orally twice daily
Study: 12514774
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 250 mg orally twice daily
Study: 12514774
Drug: Matched oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched oral placebo twice daily
Study: 8961069
Drug: lisinopril or
Normalized name: lisinopril Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril or captopril
Study: 1761082
Drug: Oral controlled
Normalized name: Afeditab CR Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral controlled release salbutamol 4 mg
Study: 1761082
Drug: Oral controlled
Normalized name: Afeditab CR Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral controlled release salbutamol 8 mg
Study: 7108069
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BD), 0.05 mg three times daily, sprayed in each nostril
Study: 2866134
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg once at night
Study: 31712971
Drug: SAMe 800
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMe 800 mg/day
Study: 25018015
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day JNJ-40929837 for 6 days followed by 50 mg/day on day 7
Study: 25018015
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day montelukast for 6 days
Study: 22080400
Drug: home‐based computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: home‐based computer vergence/accommodative therapy and pencil push‐ups
Study: 22080400
Drug: office‐based vergence/accommodative
Approvals — FDA: no, EMA: no, PMDA: no
Description: office‐based vergence/accommodative therapy with home reinforcement
Study: 22080400
Drug: office‐based placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: office‐based placebo therapy with home reinforcement
Study: 21079217
Drug: Transdermal DHT
Normalized name: stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal DHT (70 mg) daily for 2 years
Study: 21079217
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel daily for 2 years
Study: 18218905
Drug: Carbohydrate ingestion
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate ingestion (CHO; sucrose) at 0.96 g.kg(‐1).h(‐1)
Study: 18218905
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) gels
Study: 11435264
Drug: Sertraline 50-150
Normalized name: sertraline 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50-150 mg for 24 weeks
Study: 11435264
Drug: Combined sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sertraline and exposure therapy
Study: 9926765
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amoxicillin and metronidazole therapy as an adjunct to mechanical treatment
Study: 9926765
Drug: Mechanical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical treatment and antibiotics
Study: 9926765
Drug: Mechanical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical treatment and placebo
Study: 8054806
Drug: Aminophylline 3
Normalized name: aminophylline 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 3 mg/kg before protamine administration
Study: 16052104
Drug: Protamine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine (maximum 650 mg)
Study: 12537671
Drug: Anti-idiotypic monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-idiotypic monoclonal antibodies (Ab2) 2H4 or 5D3 with aluminum hydroxide-precipitated, accompanying radiotherapy
Study: 7600887
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement every other two days
Study: 7600887
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement each week
Study: 7600887
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement every day
Study: 1699764
Drug: Etodolac 200
Normalized name: etodolac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 200 or 300 mg b.i.d. or 200 mg t.i.d.
Study: 1699764
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg b.i.d. or 50 mg t.i.d.
Study: 31327127
Drug: Albuterol (β-agonist)
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (β-agonist)
Study: 22265360
Drug: Medication alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication alone (risperidone 0.5 to 3.5 mg/day; n = 49)
Study: 22265360
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus parent training (average of 11.4 PT sessions; n = 75)
Study: 22265360
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus parent training (n = 75)
Study: 17686658
Drug: Continuous Epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Epidural Infusion (CEI) at 10 mL/h
Study: 17686658
Drug: CEI +
Normalized name: Ceiba pentandra fiber
DrugBank: Ceiba pentandra fiber (DB10411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEI + Patient-Controlled Epidural Analgesia (PCEA) at 5 mL/h with demand dose of 5 mL every 20 minutes
Study: 17686658
Drug: Demand dose-only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demand dose-only PCEA (5 mL every 15 minutes)
Study: 11889779
Drug: 1% ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ketamine 2 ml
Study: 8694217
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2 ml
Study: 10725769
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of inulin with 210 mg of calcium